Luminex Q1 Revenues Up 9 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 9 percent thanks in large part to a 39 percent increase in system revenues and record revenues from assays and royalties.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $63.0 million, up from $57.7 million a year ago, and beating the consensus Wall Street estimate of $61.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.